[1] The indium industry is primarily based in Japan, where the majority of cases have been reported.
Symptoms include dyspnea (shortness of breath), cough, and increased sputum production.
[1] Other symptoms seen in some but not all cases include digital clubbing, low DLCO (capacity to move oxygen from the alveoli into the blood), and lowered forced expiratory volume.
CT abnormalities include ground-glass opacities, interlobular septal thickening, honeycombing, and bronchiectasis.
[2] The National Institute of Occupational Safety and Health, Japan (JNIOSH) set limits for acceptable exposure at 0.0003 mg/m3 after the discovery of indium lung.